Sign in with Google
bullish
Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction
351 Views26 Jul 2022 03:44
Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in its follow-on offering.
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Toyota Industries (6201) - Thinking About How To Value a ¥6trln Bid
- Shibaura Elec (6957) - Minebea Overbids Yageo's Overbid of Minebea's Overbid of Yageo - ¥5,500
- UK: Tax Hikes Disrupt Housing Market
- SONY (6758) | Going into Earnings
- Swiggy (SWIGGY IN): Post-IPO Global Index Inclusion & Final Lockup Expires In May 2025
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction26 Jul 2022
- Legend Biotech (传奇生物) Follow-On Offering - Untimely Raise15 Dec 2021
- Legend Biotech (传奇生物) IPO Trading: +27% Upside from Pricing05 Jun 2020
x